travoprost ophthalmic / Generic mfg. - LARVOL DELTA

Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty. (PubMed, Arq Bras Oftalmol) - "Chronic use of prostaglandin analogs is associated with notable periorbital changes and increased lower eyelid tension, potentially affecting aesthetics and ocular function. Pascal selective laser trabeculoplasty may offer a safer profile for preserving periorbital anatomy while maintaining effective intraocular pressure control. Laser trabeculoplasty should be considered as an initial treatment when appropriate to minimize cosmetic and functional changes from chronic topical therapy."

Clinical • Journal

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone (clinicaltrials.gov) - P3 | N=230 | Recruiting | Sponsor: Glaukos Corporation | N=150 ➔ 230 | Trial completion date: Nov 2025 ➔ Feb 2028 | Trial primary completion date: Feb 2025 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Implants to Treat Glaucoma: Promising or Not? (PubMed, Drugs Aging) - "The biodegradable bimatoprost implant releases the drug continuously for 4-6 months, and its effect on IOP may extend for up to 2 years in 25% of patients. The non-biodegradable intracameral implant releases travoprost for 36 months, when it needs to be removed...Several other biodegradable intracameral implants that release prostaglandin analogues are undergoing clinical trials. In the future, intraocular implants containing genetically modified cells that secrete neurotrophic factors may potentially offer an IOP-independent neuroprotective strategy, complementing existing IOP-lowering implants in glaucoma management."

Journal • Review • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Impact of Preservative-Free Travoprost on Intraocular Pressure and Ocular Surface in Primary Open-Angle Glaucoma Patients. (PubMed, Life (Basel)) - "Preservative-free travoprost effectively reduces IOP while improving ocular surface health, particularly in tear production and conjunctival hyperemia."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking another addition to its growing US generics portfolio. (Business Upturn)

ANDA • Ophthalmology

Evaluation of Travoprost Prescribing and Safety in the Management of Glaucoma at VA Southern Oregon Rehabilitation Center and Clinics (SORCC) (ASHP 2025) - No abstract available

Clinical • Glaucoma • Ophthalmology

Travoprost intraocular implants: pioneering a new approach in ocular hypertension management. (PubMed, Ann Med Surg (Lond)) - "While travoprost, a highly effective topical prostaglandin FP analogue, is frequently prescribed for patients with increased intraocular pressure, it presents challenges such as complex dosing regimens, poor adherence, and an increased risk of side effects stemming from chronic topical use. This comprehensive narrative review systematically investigates the contemporary status of travoprost intraocular implant, a device specifically engineered for sustained drug delivery to overcome the limitations of conventional topical travoprost formulations.The review synthesizes findings from studies discussing these implants and critically analyses the safety, efficacy profiles and patient tolerability detailed, including the two recent Phase 3 trials that led to its FDA approval, contextualizing them against other treatment modalities and therapies.While the advent of the iDose TR device marks a significant mark in the treatment and management of glaucoma and OHT, this review..."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology

Severe Microbial Keratitis Secondary to Prostaglandin-Associated Periorbitopathy. (PubMed, Case Rep Ophthalmol Med) - "Prostaglandin-associated periorbitopathy (PAP) is a known complication of prostaglandin therapy most commonly associated with topical bimatoprost...The authors report a case of PAP-induced lagophthalmos and secondary microbial keratitis that necessitated a corneal graft. Reversal of these findings occurred on prostaglandin cessation with dramatic reversal of findings within 8 weeks."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation. (PubMed, J Clin Med) - "The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma."

Journal • Glaucoma • Ophthalmology

Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana. (PubMed, PLOS Glob Public Health) - "Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

Progressive Visual Field Loss in the Setting of Severe Orbital Fat Atrophy. (PubMed, Cureus) - "This study explores the complex case of an 81-year-old female with primary open-angle glaucoma, initially treated with travoprost...This case highlights the complex nature of glaucoma management, emphasizing the impact of mechanical stress on the optic nerve and the role of prostaglandin-induced orbital atrophy. The findings underscore the importance of personalized approaches, considering both pharmacological effects and individual anatomical variations."

Journal • Glaucoma • Hematological Disorders • Obstructive Sleep Apnea • Ophthalmology • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Effect of Topical Travoprost 0.004% Drops on Central Corneal Thickness in Patients With Primary Open-Angle Glaucoma. (PubMed, Cureus) - "Conclusions Decreased CCT (30 µm or more) was observed in seven (6%) patients. Early CCT reduction with travoprost is usually subclinical, with only 6% of eyes showing ≥30 µm decrease. Although generally mild, such changes may influence IOP readings and glaucoma management, warranting further long-term study of prostaglandin effects on the cornea."

Journal • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=28 | Terminated | Sponsor: University of Miami | N=500 ➔ 28 | Completed ➔ Terminated; No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Enrollment change • Trial termination • Glaucoma • Ophthalmology

Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate and compare the effectiveness and safety of latanoprost, bimatoprost, travoprost, and tafluprost in lowering intraocular pressure (IOP) in individuals with glaucoma or ocular hypertension. Latanoprost and tafluprost offered balanced efficacy with better tolerability, making them suitable for patients with mild disease. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034803."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

Evaluating the potential of travoprost-thymoquinone co-loaded liposomes: a glaucomatous rabbit model study. (PubMed, Ther Deliv) - "The IOP-lowering efficacy was evaluated in an in vivo glaucomatous rabbit model, where significant reductions in IOP were observed, underscoring the potential of co-delivering TQ and TP via liposomes to ameliorate glaucomatous damage. Results suggest that LP-TP-TQ presents a promising strategy for advancing glaucoma management, laying the groundwork for future clinical investigations."

Journal • Preclinical • Glaucoma • Ophthalmology

NEUROPA: Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues (clinicaltrials.gov) - P=N/A | N=1500 | Not yet recruiting | Sponsor: Association for Innovation and Biomedical Research on Light and Image

New trial • Glaucoma • Ophthalmology

The effect of travoprost on primary human limbal epithelial cells and the siRNA-based aniridia limbal epithelial cell model, in vitro. (PubMed, PLoS One) - "Travoprost, at specific concentrations, can reduce the viability and proliferation of limbal epithelial cells. At 0.313 μg/mL, it significantly upregulates JNK1/2 and MMP9 expression, thereby enhancing the migratory capacity of PAX6-knockdown LECs. These findings may offer valuable insights for the selection of antiglaucomatous medications in patients with congenital aniridia."

Journal • Preclinical • Glaucoma • Inflammation • Ophthalmology • CASP3 • FOSL2 • MAPK8 • MMP9 • PAX6

Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases. (PubMed, Int J Nanomedicine) - "For instance, Ocular Therapeutix (OTX)-TP, a sustained-release intracanalicular implant combining poly (ethylene glycol)-based hydrogel with travoprost-loaded poly (lactic acid) microspheres, has shown therapeutic efficacy lasting up to three months in the management of glaucoma and ocular hypertension in Phase III clinical trial. Additionally, a liposomal formulation of verteporfin, approved for the treatment of neovascular AMD, administered intravenously and activated by laser photodynamic therapy, demonstrates a durable response, with a marked reduction in treatment frequency from an average of 3.5 sessions in the first year to only 0.1 by the fifth year post-diagnosis. Despite these advantages, challenges such as manufacturing costs, potential toxicity, and limited clinical translation persist. Future advancements in nanomedicine hold potential for personalized, non-invasive ocular therapies, revolutionizing ophthalmology."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Retinopathy • Dry Eye Disease • Glaucoma • Keratitis • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Uveitis • Wet Age-related Macular Degeneration

Increased sensitivity of primary aniridia limbal stromal cells to travoprost, leading to elevated migration and MMP-9 protein levels, in vitro. (PubMed, PLoS One) - "Travoprost may affect viability, proliferation, and migration of both LSCs and AN-LSCs, with AN-LSCs exhibiting greater sensitivity than LSCs. Additionally, travoprost may regulate MMP-9 expression in AN-LSCs via the JNK signaling pathway. Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels."

Journal • Preclinical • Glaucoma • Inflammation • Ophthalmology • FABP5 • MAPK8 • MMP3 • MMP9 • PAX6

Nitrogen-doped carbon dots-based fluorescent nanoprobe for ultra-sensitive detection of travoprost acid in aqueous humor: Greenness and blueness assessment with intensive pharmacokinetic study. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Furthermore, the method's applicability was evaluated by studying the pharmacokinetic properties of TRV acid in AH. The environmental impact of the method was evaluated using various greenness assessment tools, confirming the eco-friendly nature of the proposed method."

Journal • PK/PD data

The paradox of treatment: ciliary effusion induced by travoprost – a case report (SOE 2025) - "This case highlights a rare but significant complication of travoprost, a frequently prescribed glaucoma medication. The patient's subtle symptoms could have been easily overlooked without high index of suspicion. When suspected, discontinuing the medication can serve as both as diagnostic test and treatment."

Case report • Clinical • Achromatopsia • Glaucoma • Ophthalmology

Hemodialysis and glaucoma (case report) (SOE 2025) - "A combined topical β-blocker and carbonic anhydrase inhibitor (Cosopt®) and a prostaglandin analog (Travatan®) were prescribed to both eyes when the intraocular pressure reached 38 and 34 mm Hg in the right and left eyes, respectively. Hemodialysis was performed routinely five times a week for 2 hours and 40 minutes using a central venous catheter. After failure of ocular treatment, glucose was administered intravenously (20% glucose 100 mL/h) during dialysis to prevent an increase in IOP."

Case report • Clinical • Cataract • Glaucoma • Ophthalmology

Degradable Hydrogel Microspheres for Drug Delivery: In Vitro Performance and Influence of E-Beam Sterilization. (PubMed, AAPS PharmSciTech) - "The present work examines the in vitro drug delivery performance of degradable microspheres (DrugMic) composed of a crosslinked hydrogel of poly(ethylene glycol), with particular interest on the effect of e-beam sterilization on the stability of loaded active substances, i.e. niflumic acid (14% w/w), tadalafil (7% w/w), travoprost (0.2% w/w), buprenorphine (1.4% w/w), teicoplanin (6% w/w), and polymyxin B (5.6% w/w). DrugMic appears to be a suitable platform for sustained drug release. The loading mode can be adapted according to the stability of the drug to irradiation."

Journal • Preclinical

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

CARDIOVASCULAR ADVERSE EVENTS ASSOCIATED WITH ANTIGLAUCOMA MEDICATIONS: A PHARMACOVIGILANCE STUDY OF THE FDA ADVERSE EVENT REPORTING SYSTEM - Abhishek Kandukuru (ACC 2025) - "Background: This study investigates the pharmacovigilance of cardiovascular adverse events (AEs) linked to three antiglaucoma medications: Acetazolamide, Latanoprost, and Travoprost. The study's key findings indicate significant associations between cardiovascular adverse events and the use of certain antiglaucoma medications. These findings underscore the need for careful cardiovascular monitoring in patients using these medications. Understanding safety signals and the effects between such drugs and cardiovascular events allows informing therapeutic practices and improving the safety of patients in practice."

Adverse events • Cardiovascular • Congestive Heart Failure • Glaucoma • Heart Failure • Ophthalmology